Intranasal administration of acetylcholinesterase inhibitors
2008
Intranasal Delivery of Acetylcholinesterase Inhibitors for Alzheimer's Disease
publication
Evidence: moderate
Author Information
Author(s): Costantino Henry R, Leonard Alexis Kays, Brandt Gordon, Johnson Paul H, Quay Steven C
Primary Institution: Nastech Pharmaceutical Company Inc.
Hypothesis
Does intranasal dosing reduce gastrointestinal-related side effects compared to oral dosing?
Conclusion
Intranasal delivery of galantamine is an effective option for treating Alzheimer's disease with fewer gastrointestinal side effects compared to oral administration.
Supporting Evidence
- Intranasal administration avoids first pass metabolism, enhancing drug delivery.
- Galantamine-lactate formulation showed increased solubility and low cytotoxicity.
- IN dosing resulted in significantly fewer emetic responses compared to oral dosing.
Takeaway
This study shows that giving medicine through the nose can help people with Alzheimer's feel better without making them feel sick like taking pills can.
Methodology
The study involved in vitro screening and in vivo testing of intranasal formulations of galantamine.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website